Integra LifeSciences Holdings (IART)
Return on equity (ROE)
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Net income | US$ in thousands | -6,944 | 67,741 | 180,550 | 169,075 | 133,892 |
| Total stockholders’ equity | US$ in thousands | 1,545,280 | 1,587,880 | 1,804,400 | 1,684,800 | 1,514,870 |
| ROE | -0.45% | 4.27% | 10.01% | 10.04% | 8.84% |
December 31, 2024 calculation
ROE = Net income ÷ Total stockholders’ equity
= $-6,944K ÷ $1,545,280K
= -0.45%
Integra LifeSciences Holdings' return on equity (ROE) has shown fluctuations in recent years. From December 31, 2020, to December 31, 2021, there was a modest increase in ROE from 8.84% to 10.04%, indicating improved efficiency in generating profits from shareholders' equity.
However, the ROE slightly declined to 10.01% by December 31, 2022. In the following year, by December 31, 2023, there was a notable decrease in ROE to 4.27%, which may raise concerns about the company's profitability and management of equity.
The most recent data point from December 31, 2024, revealed a negative ROE of -0.45%, suggesting that the company's net income was insufficient to cover shareholders' equity, which could be a red flag for investors and stakeholders.
Overall, the trend in Integra LifeSciences Holdings' ROE over the years shows a mix of positive and concerning developments, indicating the need for further analysis into the factors influencing the company's profitability and efficiency in utilizing shareholders' equity.
Peer comparison
Dec 31, 2024